摘要
目的 :观察布地奈德福莫特罗、孟鲁司特钠联合脱敏疗法治疗过敏性鼻炎哮喘综合征(CARAS)的效果。方法 :选取2010年6月～2016年6月收治的80例CARAS者,随机分为对照组1、2、3和观察组。对照组1单独使用布地奈德福莫特罗,对照组2单独使用孟鲁司特钠,对照组3组联合使用布地奈德福莫特罗+孟鲁司特钠,观察组联合使用布地奈德福莫特罗+孟鲁司特钠+脱敏疗法。疗程3个月。治疗前后,检测患者CARAS临床症状评分、肺功能和血清免疫学IgE水平。结果 :治疗后,4组患者CARAS的鼻炎症状和哮喘症状评分均下降,且观察组下降程度更明显;所有患者肺功能改善,但4组间FEV1和PEFR比较没有统计学差异。所有患者血清IgE水平降低,观察组降低程度最大,对过敏反应的治疗效果更好。结论 :布地奈德福莫特罗、孟鲁司特钠联合脱敏疗法能够改善CARAS患者的主要临床症状、肺功能和过敏反应,治疗效果最好。
Objective To observe the effect of budesonide/formoterol, montelukast sodium combined with desensitization therapy in the treatment of allergic rhinitis asthma syndrome(CARAS). Methods 80 patients with CARAS treated for June, 2010 ～ June, 2016 were randomly divided into the control group 1, 2, 3 and the observation group. The cases in control group 1 were treated by budesonide/formoterol; the cases in control group 2 were treated by montelukast sodium; the cases in control 3 group were treated by budesonide/formoterol combined with montelukast sodium; the cases in observation group were treated by with budesonide/formoterol and montelukast sodium combined with desensitization therapy. The course of treatment is 3 months. Before and after treatment, the CARAS clinical symptom score, pulmonary function and serum immunological IgE level were detected. Results After treatment, four groups of patients with CARAS symptoms of rhinitis and asthma symptom scores decreased, and the observation group decreased more obviously. All patients’ lung function were proved, but between the four groups FEV1 and PEFR have no statistical difference. The serum IgE levels were decreased in all patients, and the lowest in the observation group. Conclusion Budesonide/formoterol, montelukast sodium combined with desensitization therapy can improve the clinical symptoms, pulmonary function and allergic reactions in patients with CARAS and have the best treatment effect.
出处
《湖南师范大学学报（医学版）》
2018年第5期65-68,共4页
Journal of Hunan Normal University(Medical Sciences)
关键词
布地奈德福莫特罗
孟鲁司特钠
脱敏疗法
过敏性鼻炎哮喘综合征
budesonide/formoterol
montelukast sodium
desensitization therapy
combined allergic rhinitis and asthma syndrome
